Discovery of a Potent and Selective FLT3 Kinase Inhibitor by Fragment Evolution

Hirofumi Nakano
h-nakano@mol.f.u-tokyo.ac.jp

Nae Saito
nae-saito@mol.f.u-tokyo.ac.jp

Hirotatsu Kojima
kojima@mol.f.u-tokyo.ac.jp

Takayoshi Okabe
tokabe@mol.f.u-tokyo.ac.jp

Tetsuo Nagano
tlong@mol.f.u-tokyo.ac.jp

1 Open Innovation Center for Drug Discovery, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.

Keywords: FLT3, acute myeloid leukemia, kinase inhibitor, fragment evolution

FLT3 (FMS-Like Tyrosine kinase 3), a member of class III receptor tyrosine kinase family, is a promising therapeutic target for acute myeloid leukemia (AML). Activating FLT3 mutations are found in approximately 30% of AML patients and associated to poor prognosis. To discover a novel FLT3 inhibitor, we performed a screening of our in-house fragment library. The screening hit was rapidly progressed to a potent and selective FLT3 inhibitor.